Articles On Noxopharm (ASX:NOX)

The ASX is expected to open higher on Tuesday after the mood surrounding the ongoing banking turmoil eased overnight and bank stocks rose. A significant player in this was North Carolina-based First Citizens, which entered an agreement t...

The ASX is poised to open higher on Tuesday US energy and bank stocks led Wall Street overnight Binance and CEO CZ were sued by the CFTC   The ASX is set to rise at the open on Tuesday. At 7.30am AEDT, the ASX 200 April futures contract w...

The ASX climbed 0.4% today after investors threatened it with a stick Mt Monger (ASX:MTM) wins the day by securing funding for it’s Canadian REE play New consumer survey suggests 42% of shoppers might be dumber than previously feared   Au...

Noxopharm (ASX:NOX) has announced that research from its inflammation-related Sofra preclinical program will be presented orally at the upcoming 15th International Congress on Systemic Lupus Erythematosus.

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Noxopharm (NOX) is set to progress to part two of its clinical trial of drug candidate Veyonda to treat prostate cancer Safety data from the company’s third cohort of patients in its DARRT-2 trial was reviewed by the Safety Steering Comm...

The ASX is set to end its four-day winning streak today The World Economic Forum began overnight Bitcoin keeps climbing to pre-FTX levels   Aussie shares are set to drift lower on Tuesday, ending a four-day winning streak. At 8am AEDT, th...

The ASX is poised to fall sharply on Friday following a plunge on Wall Street Nasdaq fell by more than 3% overnight The BoE and ECB hikes rates by 50bp   Local shares are set to fall sharply on Friday as US tech stocks plummeted overnight...

Australian company Noxopharm (ASX:NOX) has provided an update on the IONIC Investigator-initiated pilot Phase 1 clinical trial of its lead oncology drug candidate Veyonda.

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Noxopharm (NOX) receives a $5.01 million rebate under the Australian Government’s Research and Development (R&D) Tax Incentive scheme for expenditure during FY22CEO Gisela Mautner says the rebate will go towards supporting the company’s...

Avita Medical successfully achieved two co-primary endpoints Noxopharm received $5.011 million in R&D rebate Avita makes crucial progress in pivotal trial Avita Medical (ASX:AVH) announced that it has achieved the co-primary endpoints...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Noxopharm (ASX:NOX) has announced the resignation of founder Dr Graham Kelly as a non-executive director in a move it describes as a natural evolution.

Wall Street slump leads the ASX into an early morning drop. Thanks, Obama Benchmark strides deeper into the red, graceful as a moose on rollerskates New Age Exploration has a mystical moment at the peak of Mount Profit Well, it’s safe to...

Noxopharm (ASX:NOX) has announced what it describes as encouraging new preclinical data from its long-term collaboration with UNSW Sydney.

Biotron commences human trial of COVID-19 Pancreatic trial news from Noxopharm and Clarity Pharma Vectus completes dosing of last cohort   Biotron (ASX:BIT) jumped 6% this morning after announcing the start of a human trial of its lead an...

Local shares will open much lower on Wednesday after a big plunge on Wall Street US CPI came in higher than expected Bitcoin slumps 10pc Local shares are set to plunge on Wednesday morning after a big selloff on Wall Street overnight. At...

Noxopharm (NOX) reports “encouraging” new preclinical data from a dual-cell therapy pancreatic cancer studyThe company received results from its collaboration with UNSW Sydney, where Noxopharm conducted an 18-month trial to test a new drug,...

ASX 200 sinks 2% Small caps get crushed, down 2.5%  Region, AUD and miners sink on weaker China activity   The local market is being dragged to hell by mining, materials and gold stocks, which are down between 4% and 5%. The S&P/ASX...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Noxopharm (ASX:NOX) has announced the addition of three US sites for its CEP-2 sarcoma study - Washington University in St Louis and two Mayo Clinic sites in Florida and Minnesota.

The Victorian Government has granted Noxopharm (ASX:NOX) collaborator Hudson Institute of Medical Research a grant of $1.45 million to fund the joint development program of novel anti-inflammatory compounds.

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

ASX Emerging Companies (XEC) index has closed 1.5% on Tuesday Index now over 10% the better since February 22 Tuesday winners: ResApp (ASX:RAP), RiversGold (ASX:RGL)    The ASX Emerging Companies (XEC) index is 1.5% higher in late trade....

Noxopharm’s (NOX) lead oncology drug Veyonda has been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA) Veyonda is used to treat soft tissue sarcoma, a broad term for cancers that start in the soft tissues...

An ASX healthcare share is racing into the green today following an update from the US Food and Drug Administration (FDA). The Noxopharm Ltd (ASX: NOX) share price has rocketed 17.19% today and is currently at 38 cents. In earlier trade,...

Highlights The ASX Small Ordinaries index was seen 0.49% up at 3,293.2, by 12:30 PM AEDT. RAP, RGL and NOX were three ASX penny stocks delivering high returns today. Making a consistent gain from penny stocks is not an easy task and i...

Noxopharm (ASX:NOX) has announced that its lead oncology drug candidate Veyonda has been granted Orphan Drug Designation by the US FDA for its use in the treatment of soft tissue sarcoma.

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

ASX to rise, but Wall Street falters on J Powell commments US stocks fell slightly overnight as US Fed chairman Jerome Powell raised the prospect of multiple ‘double-shot’ (50 basis point) rate hikes in 2022, adding that the first one could...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The study investigates NOX's flagship treatment, Veyonda, in combination with the chemotherapy drug doxorubicin for the treatment of patients with soft tissue sarcoma, an aggressive cancer in urgent need of new treatment options.

The company has a substantial arsenal of products and is channelling more funds into R&D to advance clinical trials, drug discovery and preclinical activities.

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

The clinical-stage drug development company is in a strong financial position following a recent R&D rebate, and is well-placed to advance a promising clinical pipeline.

The ASX has recovered following yesterday’s strong blow, closing up 1.29% with all 11 sectors finishing in the green on lower than normal trading volumes. Today’s biggest sector win was energy, up a nice 2.20% with the financial market foll...

Noxopharm (NOX) receives a $5.8 million cash refund under the Federal Government’s Research and Development rebate for FY21 The refund further strengthens its cash position from $23.6 million on September 30 The company says the refunded c...

The cash injection adds to Noxopharm’s robust cash position, which stood at A$23.6 million as of September 30, 2021.

The ASX is down -0.3% today with the information technology sector taking the cake for the biggest dip at ~3%, followed by the healthcare sector at more than 1.5%. The ASX Emerging Companies Index (XEC) has flatlined. For the second day in...

The ASX 200 Health Index (XHJ) is falling by 1.5% at the time of writing, compared to the broader index which is down by 0.30%. Two ASX-listed companies will be presenting at the annual H.C. Wainwright BIOCONNECT Virtual Conference, to be h...

The Noxopharm Ltd (ASX: NOX) share price has leapt 6% this morning after announcing a change in executive leadership. The move coincides with the drug development company’s goal to position itself on the global stage. At the time of writi...

“Noxopharm is a unique company. I feel very honoured to be chosen as its next CEO and I am excited to lead the company through its next stages,” Dr Mautner said.

Noxopharm Limited (NOX) announces a shift in leadership in preparation for an upcoming ‘growth phase’ Dr Gisela Mautner has been appointed as CEO starting next month, with former CEO Dr Graham Kelly remaining on the board Dr Mautner joined...

Dow Jones hits fresh highs US stocks finished in mixed territories overnight. The Dow index rose 0.59%, but both S&P 500 and Nasdaq slumped by 0.06% and 1.33% respectively. Banks, industrials, and tech stocks led, following more evidenc...